CN103127502A - 使用il-21和单克隆抗体疗法治疗癌症的方法 - Google Patents

使用il-21和单克隆抗体疗法治疗癌症的方法 Download PDF

Info

Publication number
CN103127502A
CN103127502A CN2013100575165A CN201310057516A CN103127502A CN 103127502 A CN103127502 A CN 103127502A CN 2013100575165 A CN2013100575165 A CN 2013100575165A CN 201310057516 A CN201310057516 A CN 201310057516A CN 103127502 A CN103127502 A CN 103127502A
Authority
CN
China
Prior art keywords
cell
polypeptide
rituximab
fragment
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2013100575165A
Other languages
English (en)
Chinese (zh)
Inventor
W·R·金德斯沃格尔
S·D·胡格赫斯
R·D·豪雷
C·H·克雷格
D·C·弗斯特
R·A·约翰逊
M·D·黑佩尔
P·V·斯瓦库玛
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zymogenetics Inc
Original Assignee
Zymogenetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zymogenetics Inc filed Critical Zymogenetics Inc
Publication of CN103127502A publication Critical patent/CN103127502A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN2013100575165A 2004-05-20 2005-05-20 使用il-21和单克隆抗体疗法治疗癌症的方法 Pending CN103127502A (zh)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US57297304P 2004-05-20 2004-05-20
US60/572,973 2004-05-20
US63538004P 2004-12-10 2004-12-10
US60/635,380 2004-12-10
US67128105P 2005-04-14 2005-04-14
US60/671,281 2005-04-14
US68044705P 2005-05-12 2005-05-12
US60/680,447 2005-05-12

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN 200580021262 Division CN101084012A (zh) 2004-05-20 2005-05-20 使用il－21和单克隆抗体疗法治疗癌症的方法

Publications (1)

Publication Number Publication Date
CN103127502A true CN103127502A (zh) 2013-06-05

Family

ID=34971701

Family Applications (2)

Application Number Title Priority Date Filing Date
CN2013100575165A Pending CN103127502A (zh) 2004-05-20 2005-05-20 使用il-21和单克隆抗体疗法治疗癌症的方法
CN2011101079712A Expired - Fee Related CN102188704B (zh) 2004-05-20 2005-05-20 使用il-21和单克隆抗体疗法治疗癌症的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN2011101079712A Expired - Fee Related CN102188704B (zh) 2004-05-20 2005-05-20 使用il-21和单克隆抗体疗法治疗癌症的方法

Country Status (15)

Country Link
US (8) US20050265966A1 (https=)
EP (4) EP2428216A3 (https=)
JP (2) JP4982373B2 (https=)
KR (1) KR101236177B1 (https=)
CN (2) CN103127502A (https=)
AU (1) AU2005245031B2 (https=)
BR (1) BRPI0511187A (https=)
CA (1) CA2566745A1 (https=)
CY (1) CY1113287T1 (https=)
DK (1) DK1758610T3 (https=)
ES (1) ES2390278T3 (https=)
IL (1) IL179099A (https=)
PL (1) PL1758610T3 (https=)
PT (1) PT1758610E (https=)
WO (1) WO2005113001A1 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6307024B1 (en) 1999-03-09 2001-10-23 Zymogenetics, Inc. Cytokine zalpha11 Ligand
BRPI0511187A (pt) * 2004-05-20 2007-12-04 Zymogenetics Inc método para tratar cáncer em um indivìduo
US20070218116A1 (en) * 2006-03-14 2007-09-20 Schwendener Reto A Compositions and methods for the treatment of tumors and tumor metastases
AU2007310777A1 (en) 2006-10-26 2008-05-02 Novo Nordisk A/S IL-21 variants
KR100902340B1 (ko) * 2007-08-02 2009-06-12 한국생명공학연구원 Ｙｃ－１ 또는 ｉｌ－２１을 유효성분으로 포함하는자연살해세포 분화제 및 분화 방법
US8506933B2 (en) * 2007-11-30 2013-08-13 Msdx, Inc. Methods of detecting a neurological condition via analysis of circulating phagocytes
WO2011019670A1 (en) * 2009-08-10 2011-02-17 Nayak Ramesh C Methods of detecting responses to therapies using perforin levels
EP2504699A1 (en) * 2009-11-27 2012-10-03 MSDX, Inc. Methods of detecting or monitoring activity of an inflammatory or neurodegenerative condition
US8673309B2 (en) 2011-02-11 2014-03-18 Msdx, Inc. Methods for measuring high molecular weight complexes of fibrinogen with fibronectin and fibulin-1
US9447160B2 (en) * 2012-01-19 2016-09-20 University Of Miami Compositions, methods and kits for treatment of cancer and autoimmune diseases
WO2013169693A1 (en) 2012-05-09 2013-11-14 Bristol-Myers Squibb Company Methods of treating cancer using an il-21 polypeptide and an anti-pd-1 antibody
KR101453462B1 (ko) 2013-05-16 2014-10-23 앱클론(주) Her2에 특이적으로 결합하는 항체
HUE051676T2 (hu) 2014-04-08 2021-03-29 Boston Pharmaceuticals Inc Il-21-re specifikus kötõ molekulák és alkalmazásaik
KR20160120157A (ko) 2015-04-07 2016-10-17 주식회사 메드팩토 암 예방 또는 치료용 약학적 조성물 및 이를 이용한 방법
US20200016200A1 (en) * 2016-10-03 2020-01-16 Baylor College Of Medicine Modulating cytotoxic cell lytic granule positioning to promote diffuse killing in cellular therapies
EP3682237A1 (en) * 2017-09-15 2020-07-22 Beckman Coulter, Inc. Flow based assays for therapeutics
KR102265437B1 (ko) * 2017-11-24 2021-06-15 의료법인 성광의료재단 Nk 배양용 조성물 및 이를 이용하여 nk 세포를 배양하는 방법

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6307024B1 (en) * 1999-03-09 2001-10-23 Zymogenetics, Inc. Cytokine zalpha11 Ligand
WO2003103589A2 (en) * 2002-06-07 2003-12-18 Zymogenetics, Inc. Use of il-21 in cancer and other therapeutic applications

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5567584A (en) 1988-01-22 1996-10-22 Zymogenetics, Inc. Methods of using biologically active dimerized polypeptide fusions to detect PDGF
DE68926888T2 (de) 1988-01-22 1997-01-09 Zymogenetics Inc Verfahren zur Herstellung von sekretierten Rezeptoranalogen
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US6057128A (en) * 1998-03-17 2000-05-02 Genetics Institute, Inc. MU-1, member of the cytokine receptor family
CA2340091C (en) * 1998-08-11 2013-02-05 Idec Pharmaceuticals Corporation Combination therapies for b-cell lymphomas comprising administration of anti-cd20 antibody
WO2001001748A2 (en) * 1999-07-02 2001-01-11 Genentech, Inc. Peptide compounds that bind her2
IT1311703B1 (it) 1999-07-23 2002-03-19 Sipa Spa Impianto ad alta efficienza di soffiaggio di preforme
ES2279809T3 (es) 2000-04-05 2007-09-01 Zymogenetics, Inc. Receptores de citoquina zalfa11 solubles.
US7306801B2 (en) * 2000-05-15 2007-12-11 Health Research, Inc. Methods of therapy for cancers characterized by overexpression of the HER2 receptor protein
JP2005538034A (ja) 2001-12-07 2005-12-15 カイロン コーポレイション 非ホジキンリンパ腫の治療方法
KR101033196B1 (ko) * 2002-02-14 2011-05-09 이뮤노메딕스, 인코오포레이티드 항-ｃｄ20 항체 및 그 융합 단백질 및 이들의 이용방법
BR0309254A (pt) * 2002-04-12 2005-03-01 Medarex Inc Uso de um anticorpo anti-ctla-4
US20040016010A1 (en) * 2002-04-17 2004-01-22 Marion Kasaian IL-21 receptor knockout animal and methods of use thereof
CN101972478B (zh) * 2002-10-08 2012-10-31 免疫医疗公司 抗体治疗
US20070092485A1 (en) * 2002-11-15 2007-04-26 Zymogenetics, Inc. Cytokine zalpha11 ligand
ES2334127T3 (es) * 2002-12-13 2010-03-05 Zymogenetics, Inc. Produccion de il-21 en huespedes procariotas.
US7465446B2 (en) 2003-05-30 2008-12-16 Medarex, Inc. Surrogate therapeutic endpoint for anti-CTLA4-based immunotherapy of disease
JP2007508332A (ja) * 2003-10-17 2007-04-05 ノボ　ノルディスク　アクティーゼルスカブ 併用療法
BRPI0511187A (pt) * 2004-05-20 2007-12-04 Zymogenetics Inc método para tratar cáncer em um indivìduo
WO2006065495A2 (en) * 2004-11-24 2006-06-22 Fred Hutchinson Cancer Research Center Methods of using il-21 for adoptive immunotherapy and identification of tumor antigens

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6307024B1 (en) * 1999-03-09 2001-10-23 Zymogenetics, Inc. Cytokine zalpha11 Ligand
WO2003103589A2 (en) * 2002-06-07 2003-12-18 Zymogenetics, Inc. Use of il-21 in cancer and other therapeutic applications

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ADRIANNA MOROZ: "IL-21 Enhances and Sustains CD8~+T Cell Responses to Achieve Durable Tumor Immunity:Comparative Evaluation of IL-2,IL-15,and IL-21", 《THE JOURNAL OF IMMUNOLOGY》 *
肖溶: "Ⅰ类细胞因子超家族新成员--IL-21", 《生命的化学》 *

Also Published As

Publication number Publication date
US20050265966A1 (en) 2005-12-01
PT1758610E (pt) 2012-10-01
CY1113287T1 (el) 2016-04-13
ES2390278T3 (es) 2012-11-08
US20110300098A1 (en) 2011-12-08
US20070178063A1 (en) 2007-08-02
EP1758610A1 (en) 2007-03-07
US20090269304A1 (en) 2009-10-29
IL179099A0 (en) 2007-03-08
KR20070026588A (ko) 2007-03-08
EP2431050A1 (en) 2012-03-21
CA2566745A1 (en) 2005-12-01
JP2007538108A (ja) 2007-12-27
BRPI0511187A (pt) 2007-12-04
WO2005113001A1 (en) 2005-12-01
EP2431050A8 (en) 2012-09-26
IL179099A (en) 2011-03-31
US20110086004A1 (en) 2011-04-14
EP2428216A2 (en) 2012-03-14
EP2425847A1 (en) 2012-03-07
EP1758610B1 (en) 2012-07-04
KR101236177B1 (ko) 2013-02-22
US20070122382A1 (en) 2007-05-31
AU2005245031A1 (en) 2005-12-01
JP4982373B2 (ja) 2012-07-25
CN102188704A (zh) 2011-09-21
US20090087404A1 (en) 2009-04-02
CN102188704B (zh) 2013-04-24
DK1758610T3 (da) 2012-10-15
AU2005245031B2 (en) 2011-08-18
PL1758610T3 (pl) 2012-11-30
HK1160776A1 (en) 2012-08-17
US20070048264A1 (en) 2007-03-01
EP2428216A3 (en) 2012-05-23
JP2012102122A (ja) 2012-05-31
EP2428216A9 (en) 2012-04-25

Similar Documents

Publication Publication Date Title
CN102188704B (zh) 使用il-21和单克隆抗体疗法治疗癌症的方法
Kohrt et al. CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies
Josephs et al. Tumour-associated macrophage polarisation and re-education with immunotherapy
Yano et al. Defucosylated anti–CC chemokine receptor 4 monoclonal antibody combined with immunomodulatory cytokines: a novel immunotherapy for aggressive/refractory mycosis fungoides and Sézary syndrome
CN118317789A (zh) 靶向bcma的p329g抗体及其与嵌合抗原受体细胞的组合和应用
Miljkovic et al. Interleukin-15 augments NK cell–mediated ADCC of alemtuzumab in patients with CD52+ T-cell malignancies
Cao et al. CD47-blocking antibody ZL-1201 promotes tumor-associated macrophage phagocytic activity and enhances the efficacy of the therapeutic antibodies and chemotherapy
CN101084012A (zh) 使用il－21和单克隆抗体疗法治疗癌症的方法
HK1160776B (en) Methods of treating cancer using il-21 and monoclonal antibody therapy
HK1167338A (en) Methods of treating cancer using il-21 and monoclonal antibody therapy
Στραβοκεφάλου The role of cellular immunity in the treatment of cancer
HK1167803A (en) Methods of treating cancer using il-21 and monoclonal antibody therapy
Visser Exploring novel therapeutic approaches for the treatment of hematological malignancies: a focus on autophagy and immunotherapy
HK1167337A (en) Methods of treating cancer using il-21 and monoclonal antibody therapy
CN118924893A (zh) Bcmap329g抗体及car-t细胞在治疗多发性骨髓瘤中的应用
Cai et al. A computationally designed Rituximab/CD3 T cell engager targeting CD20+ cancers with multiple mechanisms of action
Solomon Targeting regulatory T cells for therapeutic gain in cancer therapy
Franz Demane Defining and targeting combination immunotherapies in mouse models of cancer
Guyre et al. FcγR-directed immunotherapies
Burlion et al. A novel combination of cyclophosphamide and anti-ICOS mAb prevents tumor growth by affecting regulatory T cells in mice with a human immune system

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20130605